PMID- 36842766
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230522
IS  - 1879-2561 (Electronic)
IS  - 0304-419X (Linking)
VI  - 1878
IP  - 3
DP  - 2023 May
TI  - To be or not to be: The double-edged sword roles of liver progenitor cells.
PG  - 188870
LID - S0304-419X(23)00019-7 [pii]
LID - 10.1016/j.bbcan.2023.188870 [doi]
AB  - Given the liver's remarkable and unique regenerative capacity, researchers have 
      long focused on liver progenitor cells (LPCs) and liver cancer stem cells 
      (LCSCs). LPCs can differentiate into both hepatocytes and cholangiocytes. 
      However, the mechanism underlying cell conversion and its distinct contribution 
      to liver homeostasis and tumorigenesis remain unclear. In this review, we discuss 
      the complicated conversions involving LPCs and LCSCs. As the critical 
      intermediate state in malignant transformation, LPCs play double-edged sword 
      roles. LPCs are not only involved in hepatic wound-healing responses by 
      supplementing liver cells and bile duct cells in the damaged liver but may 
      transform into LCSCs under dysregulation of key signaling pathways, resulting in 
      refractory malignant liver tumors. Because LPC lineages are temporally and 
      spatially dynamic, we discuss crucial LPC subgroups and summarize regulatory 
      factors correlating with the trajectories of LPCs and LCSCs in the liver tumor 
      microenvironment. This review elaborates on the double-edged sword roles of LPCs 
      to help understand the liver's regenerative potential and tumor heterogeneity. 
      Understanding the sources and transformations of LPCs is essential in determining 
      how to exploit their regenerative capacity in the future.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Yan, Zi-Jun
AU  - Yan ZJ
AD  - International Cooperation Laboratory on Signal Transduction, Eastern 
      Hepatobiliary Surgery Hospital/National Center for Liver Cancer, Shanghai 200438, 
      PR China; Key Laboratory of Signaling Regulation and Targeting Therapy of Liver 
      Cancer (SMMU), Ministry of Education, Shanghai 200438, PR China; Shanghai Key 
      Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, PR China.
FAU - Chen, Lei
AU  - Chen L
AD  - International Cooperation Laboratory on Signal Transduction, Eastern 
      Hepatobiliary Surgery Hospital/National Center for Liver Cancer, Shanghai 200438, 
      PR China; Key Laboratory of Signaling Regulation and Targeting Therapy of Liver 
      Cancer (SMMU), Ministry of Education, Shanghai 200438, PR China; Shanghai Key 
      Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, PR China. 
      Electronic address: chenlein39@hotmail.com.
FAU - Wang, Hong-Yang
AU  - Wang HY
AD  - International Cooperation Laboratory on Signal Transduction, Eastern 
      Hepatobiliary Surgery Hospital/National Center for Liver Cancer, Shanghai 200438, 
      PR China; Key Laboratory of Signaling Regulation and Targeting Therapy of Liver 
      Cancer (SMMU), Ministry of Education, Shanghai 200438, PR China; Shanghai Key 
      Laboratory of Hepatobiliary Tumor Biology (EHBH), Shanghai 200438, PR China. 
      Electronic address: hywangk@vip.sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230224
PL  - Netherlands
TA  - Biochim Biophys Acta Rev Cancer
JT  - Biochimica et biophysica acta. Reviews on cancer
JID - 9806362
SB  - IM
MH  - Humans
MH  - Cell Differentiation
MH  - *Hepatocytes/pathology/physiology
MH  - *Liver Neoplasms/pathology
MH  - Neoplastic Stem Cells/pathology
MH  - Cell Transformation, Neoplastic
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Heterogeneity
OT  - Liver cancer stem cells
OT  - Liver progenitor cells
OT  - Stemness
COIS- Declaration of Competing Interest All authors have declared no conflict of 
      interest.
EDAT- 2023/02/27 06:00
MHDA- 2023/05/22 06:42
CRDT- 2023/02/26 19:34
PHST- 2022/11/23 00:00 [received]
PHST- 2023/01/11 00:00 [revised]
PHST- 2023/01/28 00:00 [accepted]
PHST- 2023/05/22 06:42 [medline]
PHST- 2023/02/27 06:00 [pubmed]
PHST- 2023/02/26 19:34 [entrez]
AID - S0304-419X(23)00019-7 [pii]
AID - 10.1016/j.bbcan.2023.188870 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188870. doi: 
      10.1016/j.bbcan.2023.188870. Epub 2023 Feb 24.